CoChat

Metabolic Syndrome: Clinical and Policy Implications of the New Silent Killer

Sherling, Dawn Harris, Perumareddi, Parvathi, Hennekens, Charles H. · 2017 · Journal of Cardiovascular Pharmacology and Therapeutics

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

The United States is experiencing its greatest life expectancy ever. Nonetheless, the general health of the US population is far from at an all-time high. An important contributor to the pandemic of cardiovascular disease is that overweight and obesity are also the major determinants of metabolic syndrome, an all too common and all too serious clinical and public health challenge. Clinicians have traditionally evaluated each of the major risk factors contributing to metabolic syndrome on an individual basis. There is evidence, however, that the risk factors are more than additive. The overlap of these factors in each disease state, resulting in increased atherogenic risks, is worth examining as a broader entity rather than separately. While therapeutic lifestyle changes (TLCs) should be strongly recommended, clinicians should not let the perfect be the enemy of the possible. Evidence-based doses of statins, aspirin and angiotensin-converting enzyme inhibitors, or angiotensin II receptor blockers should be prescribed as adjuncts, not alternatives, to TLCs. In fact, there is cogent evidence that the benefits of these pharmacologic therapies may also be at least additive.

Overview

Integrity signals

Registry

Crossref · 10.1177/1074248416686187

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 11 references

Cited by

See all 294

Metadata

Authors
Sherling, D. H., Perumareddi, P., & Hennekens, C. H.
Affiliations
Florida Atlantic University (US)
Corresponding author
Sherling, Dawn Harris
Venue
Journal of Cardiovascular Pharmacology and Therapeutics
Published
2017-01-09
Volume
22
Issue
4
Pages
365-367
ISSN
  • 1074-2484 (ISSN-L)
  • 1940-4034
OpenAlex
W2571450722
Cited by
268
References
11
Citations by year
2026: 5 · 2025: 17 · 2024: 24 · 2023: 25 · 2022: 39 · 2021: 50 · 2020: 67 · 2019: 30 · 2018: 7 · 2017: 4
FWCI
23.34
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Journal of Cardiovascular Pharmacology and Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
metabolic syndrome, cardiovascular disease, obesity, overweight, atherogenic risk, therapeutic lifestyle changes, statins, aspirin, ACE inhibitors, angiotensin receptor blockers, pharmacotherapy
MeSH terms
Healthy Lifestyle, Diet, Healthy, Animals, Health Status, Humans, Prognosis, Risk Factors, Exercise, Metabolic Syndrome, Risk Reduction Behavior, Protective Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metabolic Syndrome: Clinical and Policy Implications of the New Silent Killer. https://app.cochat.ai/papers/10.1177/1074248416686187
The paper
Sherling, D. H., Perumareddi, P., & Hennekens, C. H. (2017). Metabolic Syndrome: Clinical and Policy Implications of the New Silent Killer. Journal of Cardiovascular Pharmacology and Therapeutics. https://doi.org/10.1177/1074248416686187

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.